Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, double-blind, placebo-controlled pilot study of WF10 in persistent allergic rhinitis
2007-006003-21Phase 2Completed
- Sponsor
- Miravo Healthcare
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) comparing WF10 with Placebo (2 arms). Primary endpoint: Change in Total Nasal Symptom Score (TNSS) from baseline to Visit F3. Started Oct 2008; status: completed.
02
Drugs
tetrachlorodecaoxide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2007-006003-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006003-21.